Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

  1. Teira, R.
  2. Diaz-Cuervo, H.
  3. Aragão, F.
  4. Castaño, M.
  5. Romero, A.
  6. Roca, B.
  7. Montero, M.
  8. Galindo, M.J.
  9. Muñoz-Sánchez, M.J.
  10. Espinosa, N.
  11. Peraire, J.
  12. Martínez, E.
  13. de la Fuente, B.
  14. Domingo, P.
  15. Deig, E.
  16. Merino, M.D.
  17. Geijo, P.
  18. Estrada, V.
  19. Sepúlveda, M.A.
  20. García, J.
  21. Berenguer, J.
  22. Currán, A.
Revue:
Infectious Diseases and Therapy

ISSN: 2193-6382,  2193-8229

Année de publication: 2022

Volumen: 11

Número: 3

Pages: 1177-1192

Type: Article

DOI: 10.1007/S40121-022-00630-Y GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus